Morphologic and functional vascular alterations in patients with polycystic ovary syndrome

被引:0
|
作者
Demir, B. [1 ]
Pasa, S. [2 ]
Demir, S. [1 ]
Buyukkaya, R. [3 ]
Atay, A. E. [4 ]
Atamer, Y. [5 ]
Gul, T. [6 ]
机构
[1] Ergani State Hosp, Dept Gyneacol & Obstet, Diyarbakir, Turkey
[2] Adiyaman Univ, Fac Med, Dept Internal Dis, Adiyaman, Turkey
[3] Ergani State Hosp, Dept Radiodiagnost, Diyarbakir, Turkey
[4] Diyarbakir Family Hosp, Dept Internal Med, Diyarbakir, Turkey
[5] Dicle Univ, Fac Med, Dept Biochem, Diyarbakir, Turkey
[6] Dicle Univ, Fac Med, Dept Gyneacol & Obstet, Diyarbakir, Turkey
来源
关键词
Polycystic ovary syndrome; Vascular alterations; Vascular dysfunction; INTIMA-MEDIA THICKNESS; CAROTID-ARTERY INTIMA; MIDDLE-AGED WOMEN; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RESISTIVE INDEX; RISK-FACTORS; YOUNG-WOMEN; ATHEROSCLEROSIS; HEART;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: We aimed to investigate morphologic and functional alterations of common carotid arteries (CCA) and femoral arteries and the anteroposterior diameter of the abdominal aorta in patients with polycystic ovary syndrome (PCOS). Materials and Methods: Fifty consecutive females with the complaint of oligoamenorrhea, infertility or hirsutismus, diagnosed with PCOS and 50 healthy females admitted to the Department of Gynecology and Obstetrics, Ergani State Hospital between January 2010 and January 2011 were included in the study. Results: The mean BMI of 50 patients with PCOS was higher than control subjects (CS) (25.89 +/- 3.3 vs 22.52 +/- 2.7 kg/m(2), p < 0.0001). The mean arterial blood pressure was 88.93 +/- 6.4 mmHg in the patient group and was it 85.73 +/- 7.6 mmHg in CS (p = 0.02). The mean plasma glucose level (74.04 +/- 6.7 vs 70.5 +/- 6.4 mg/dl), total cholesterol level (167.88 +/- 30.1 vs 153.38 +/- 27.8 mg/di), low density lipoprotein level (101.28 +/- 27.0 vs 79.56 +/- 25.5 mg/dl) and triglyceride level (121.22 +/- 49.2 vs 102.54 +/- 36.6 mg/di) were higher; also the mean high density lipoprotein level (44.56 +/- 8.1 vs 50.90 +/- 12.3 mg/dl) was lower in patients with PCOS than CS (p = 0.009, p = 0.014, p < 0.0001, p = 0.034 and p = 0.003, respectively). CCA-IMT (0.63 +/- 0.2 vs 0.52 +/- 0.1 mm), and CCA-PI (1.44 +/- 0.3 vs 1.28 +/- 0.22) were higher in patients with PCOS (p = 0.018 and p = 0.005, respectively). Femoral-IMT (0.62 +/- 0.6 vs 0.41 +/- 0.1 mm) and anteroposterior diameter of the infrarenal aorta (12.34 +/- 1.5 vs 11.4 +/- 1.0 mm) were higher in patients with PCOS (p = 0.024 and p = 0.001, respectively). Conclusion: The present study showed that IMT and PI of CCA, and anteroposterior diameter of the infrarenal abdominal aorta and femoral-IMT were higher in patients with PCOS. These results are probably related with increased androgens, their effects on insulin resistance and lipid profile, increased BMI and blood pressure. Detection of these functional and/or structural abnormalities are important in predicting prognosis. Larger scale prospective studies are needed to determine the effects of PCOS on the mortality and morbidity, and to clarify the relation between the duration of the disease and development of these alterations.
引用
收藏
页码:401 / 404
页数:4
相关论文
共 50 条
  • [1] Tear function alterations in patients with polycystic ovary syndrome
    Yuksel, B.
    Ozturk, I.
    Seven, A.
    Aktas, S.
    Aktas, H.
    Kucur, S. K.
    Polat, M.
    Kilic, S.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (19) : 3556 - 3562
  • [2] Immunological alterations in polycystic ovary syndrome
    Bazzano, Maria Victoria
    Koeninger, Angela
    Solano, Maria Emilia
    [J]. GYNAKOLOGISCHE ENDOKRINOLOGIE, 2023, : 231 - 239
  • [3] Vascular risk in young women with polycystic ovary and polycystic ovary syndrome
    Battaglia, Cesare
    Mancini, Fulvia
    Cianciosi, Arianna
    Busacchi, Paolo
    Facchinetti, Fabio
    Marchesini, Giulio Reggiani
    Marzocchi, Rebecca
    de Aloysio, Domenico
    [J]. OBSTETRICS AND GYNECOLOGY, 2008, 111 (02): : 385 - 395
  • [4] Alterations of folliculogenesis in women with polycystic ovary syndrome
    Analia Sander, Valeria
    Belen Hapon, Maria
    Sicaro, Laura
    Pedro Lombardi, Eduardo
    Alma Jahn, Graciela
    Beatriz Motta, Alicia
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2011, 124 (1-2): : 58 - 64
  • [5] Meibomian gland alterations in polycystic ovary syndrome
    Yavas, Guliz Fatma
    Ozturk, Faruk
    Kusbeci, Tuncay
    Ermis, Sitki Samet
    Yilmazer, Mehmet
    Cevrioglu, Serhan
    Aktepe, Fatma
    Kose, Songul
    [J]. CURRENT EYE RESEARCH, 2008, 33 (02) : 133 - 138
  • [6] TREATMENT OF METABOLIC ALTERATIONS IN POLYCYSTIC OVARY SYNDROME
    Pavaleanu, Ioana
    Gafitanu, D.
    Popovici, Diana
    Duceac, Letitia Doina
    Pavaleanu, Maricica
    [J]. MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2016, 120 (02): : 258 - 263
  • [7] Functional aspects of HDL in patients with polycystic ovary syndrome (PCOS)
    Amancio, R. F.
    Rocha, M. P.
    Marcondes, J. A.
    Barcellos, C. R.
    Latrilha, M. C.
    Maranhao, R. C.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 535 - 535
  • [8] Peripheral catecholamine alterations in adolescents with polycystic ovary syndrome
    Garcia-Rudaz, C
    Armando, I
    Levin, G
    Escobar, ME
    Barontini, M
    [J]. CLINICAL ENDOCRINOLOGY, 1998, 49 (02) : 221 - 228
  • [9] Alterations in nasal mucociliary activity in polycystic ovary syndrome
    Kucur, Suna Kabil
    Seven, Ali
    Yuksel, Beril
    Kucur, Cuneyt
    Sencan, Halime
    Gozukara, Ilay
    Keskin, Nadi
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2016, 207 : 169 - 172
  • [10] The risk of functional ovarian hyperandrogenism and polycystic ovary syndrome in patients with hyperandrogenism
    Çetinkaya, E
    Ocal, G
    Berberoglu, M
    Adiyaman, P
    [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2003, 16 (07): : 1011 - 1016